Last reviewed · How we verify

L-selenomethionine

SWOG Cancer Research Network · Phase 3 active Small molecule Quality 3/100

L-selenomethionine is a Small molecule drug developed by SWOG Cancer Research Network. It is currently in Phase 3 development. Also known as: Selenium, placebo.

At a glance

Generic nameL-selenomethionine
Also known asSelenium, placebo
SponsorSWOG Cancer Research Network
ModalitySmall molecule
PhasePhase 3

Approved indications

No approved indications tracked.

Common side effects

No common side effects on file.

Key clinical trials

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

SourceUsed for
ClinicalTrials.govTrial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

Frequently asked questions about L-selenomethionine

What is L-selenomethionine?

L-selenomethionine is a Small molecule drug developed by SWOG Cancer Research Network.

Who makes L-selenomethionine?

L-selenomethionine is developed by SWOG Cancer Research Network (see full SWOG Cancer Research Network pipeline at /company/swog-cancer-research-network).

Is L-selenomethionine also known as anything else?

L-selenomethionine is also known as Selenium, placebo.

What development phase is L-selenomethionine in?

L-selenomethionine is in Phase 3.

Related